On HIV diversity.

HIV type 1 (HIV-1) displays a greater degree of genetic and antigenic variability than any other virus studied. This diversity reflects a high mutation rate during viral replication with a large turnover of virus, and a high tolerance of variation while maintaining reproductive capacity. Generation of diversity is a common property of lentiviruses such as HIV. Differences in virulence and in transmissibility are seen between different HIV-1 strains which may have clinical implications. The great degree of HIV diversity presents challenges to maintaining sensitivity to antiretroviral therapy and to the development of preventive strategies such as microbicides and vaccines.

[1]  R. Koup.  Virus escape from CTL recognition , 1994, The Journal of experimental medicine.

[2]  Yang Liu,et al.  Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[3]  V. Pathak,et al.  Recombinant Origin of the Retrovirus XMRV , 2011 .

[4]  Dennis R Burton,et al.  A Boost for HIV Vaccine Design , 2010, Science.

[5]  R. Cheynier,et al.  LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur. , 1991, Science.

[6]  K. D. de Cock.  The Origins of AIDS , 2012, Emerging Infectious Diseases.

[7]  P. Sharp,et al.  The evolution of HIV-1 and the origin of AIDS , 2010, Philosophical Transactions of the Royal Society B: Biological Sciences.

[8]  P. Ghys,et al.  Global trends in molecular epidemiology of HIV-1 during 2000–2007 , 2011, AIDS.

[9]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[10]  C. Williamson,et al.  Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. , 2012, The Journal of infectious diseases.

[11]  E. Sabino,et al.  Faster HIV-1 Disease Progression among Brazilian Individuals Recently Infected with CXCR4-Utilizing Strains , 2012, PloS one.

[12]  J. L. Raina,et al.  Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. , 1992, Virology.

[13]  Clare Jolly,et al.  HIV-1 Cell to Cell Transfer across an Env-induced, Actin-dependent Synapse , 2004, The Journal of experimental medicine.

[14]  I. Williams,et al.  In Vivo Emergence of HIV-1 Highly Sensitive to Neutralizing Antibodies , 2011, PloS one.

[15]  Christophe Fraser,et al.  HIV-1 transmission, by stage of infection. , 2008, The Journal of infectious diseases.

[16]  D. Richman,et al.  The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.

[17]  R. Weiss,et al.  Virulence and pathogenesis. , 2002, Trends in microbiology.

[18]  P. Easterbrook,et al.  Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy , 2010, Journal of the International AIDS Society.

[19]  C. Rousseau,et al.  Subtype C Is associated with increased vaginal shedding of HIV-1. , 2005, The Journal of infectious diseases.

[20]  J. Levy,et al.  HIV and the Pathogenesis of AIDS , 1994, Nature Medicine.

[21]  David Heckerman,et al.  Adaptation of HIV-1 to human leukocyte antigen class I , 2009, Nature.

[22]  P. Piot,et al.  Prevention of sexual transmission of HIV: real results, science progressing, societies remaining behind. , 2012, AIDS.

[23]  T. Kepler,et al.  Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design , 2012, Journal of Virology.

[24]  P. Kaleebu,et al.  Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort , 2001, AIDS.

[25]  J. Mellors,et al.  Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.

[26]  Cynthia A. Derdeyn,et al.  Molecular Epidemiology of Human Immunodeficiency Virus Type 1 Transmission in a Heterosexual Cohort of Discordant Couples in Zambia , 2002, Journal of Virology.

[27]  D. Price,et al.  CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[28]  G. Bocharov,et al.  Recombination: Multiply infected spleen cells in HIV patients , 2002, Nature.

[29]  M. Aasa-Chapman,et al.  Humoral immunity to HIV-1: neutralisation and antibody effector functions. , 2008, Trends in microbiology.

[30]  Ashley T. Haase,et al.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS , 1993, Nature.

[31]  T. Chun,et al.  HIV reservoirs: pathogenesis and obstacles to viral eradication and cure , 2012, AIDS.

[32]  G. Nabel,et al.  The design and evaluation of HIV-1 vaccines. , 2012, AIDS.

[33]  Feng Gao,et al.  Dynamic Antibody Specificities and Virion Concentrations in Circulating Immune Complexes in Acute to Chronic HIV-1 Infection , 2011, Journal of Virology.

[34]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[35]  L. H. Liow,et al.  Red Queen: from populations to taxa and communities. , 2011, Trends in ecology & evolution.

[36]  G. Learn,et al.  HIV-1 Nomenclature Proposal , 2000, Science.

[37]  Astrid Gall,et al.  Evolutionary Dynamics of Local Pandemic H1N1/2009 Influenza Virus Lineages Revealed by Whole-Genome Analysis , 2011, Journal of Virology.

[38]  P. Bieniasz.  An overview of intracellular interactions between immunodeficiency viruses and their hosts , 2012, AIDS.

[39]  B. Korber,et al.  A new classification for HIV-1 , 1998, Nature.

[40]  R. Weiss,et al.  Why is HIV a pathogen? , 2008, Trends in microbiology.

[41]  B. Haynes,et al.  Acute HIV-1 Infection. , 2011, The New England journal of medicine.

[42]  M. Malim,et al.  APOBEC proteins and intrinsic resistance to HIV-1 infection , 2009, Philosophical Transactions of the Royal Society B: Biological Sciences.

[43]  B. Korber,et al.  Evolutionary and immunological implications of contemporary HIV-1 variation. , 2001, British medical bulletin.

[44]  Anthony S. Fauci,et al.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease , 1993, Nature.

[45]  P. Vernazza,et al.  Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants , 1999, Journal of Virology.

[46]  S. J. Potter,et al.  Molecular cloning of AIDS-associated retrovirus , 1984, Nature.

[47]  B. Schwartländer,et al.  The history of antiretroviral therapy and of its implementation in resource-limited areas of the world , 2012, AIDS.

[48]  Lynn Morris,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.

[49]  Bette Korber,et al.  HIV Evolution in Early Infection: Selection Pressures, Patterns of Insertion and Deletion, and the Impact of APOBEC , 2009, PLoS pathogens.

[50]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[51]  R. Weiss,et al.  Detection and quantitation of human immunodeficiency virus type-1 particles by confocal microscopy. , 2004, Journal of virological methods.

[52]  C. Moore,et al.  Evidence of HIV-1 Adaptation to HLA-Restricted Immune Responses at a Population Level , 2002, Science.

[53]  T. F. Rinke de Wit,et al.  HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. , 1999, AIDS.

[54]  D. Montefiori,et al.  Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. , 2010, The Journal of general virology.

[55]  Charles R. M. Bangham,et al.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition , 1991, Nature.

[56]  A. Lackner,et al.  Getting to the Guts of HIV Pathogenesis , 2004, The Journal of experimental medicine.

[57]  David Heckerman,et al.  Gag-Protease-Mediated Replication Capacity in HIV-1 Subtype C Chronic Infection: Associations with HLA Type and Clinical Parameters , 2010, Journal of Virology.

[58]  Tongqing Zhou,et al.  Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.

[59]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[60]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[61]  J. Ball,et al.  Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis. , 2010, Future virology.

[62]  R. Koup,et al.  CD8+ T cells in preventing HIV infection and disease , 2012, AIDS.

[63]  G. Gottlieb,et al.  Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission , 2012, AIDS.